Bristol Myers good performingI found a strong sector because there are strongly proves the pharmaceuticals helps to improve the quality of life and increases life expectancyLongby fritzkuri5
BMY offers short term gains.We are of the opinion that the recent resistance level @ $54 looks on the near term horizon, momentum has been strong, but volume is on the decline. Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY. Longby Bullishcharts15
Rising Channel in BMYI identified rising channel developing in BMY, it seems that I might enter it too late. However, the momentum in the market for Healthcare is strong. I bought a call vertical for the trade Entry: Longby RiskRewardRatioUpdated 3
Bearish Regular DivergenceBearish Regular Divergence can be seen on the 3/4 hour chartShortby sweenejo1
[Idea Long] BMY and CELGNice wedge pattern on this. Although it's been in a downtrend, it weathered the past week's volatility quite well, so my guess is sellers are exhausted here in the short-medium term. This is a $75B global pharmaceutical company, makes a bunch of important drugs, that is trading at 12 P/E and pays 3.5% dividend. They are acquiring Celgene (CELG), a similar company that trades at 13 P/E. At the deal's closing, holders of CELG stock will receive 1 BMY stock plus $50. An attractive way to play this would be to buy CELG stock, and get assigned BMY plus $50. That adds a bonus $2 per share on the deal's closing. I had my eye on this but missed the chance to buy the dip. The chart of CELG has a nice looking gap fill: This could be prove to be a long term entry area.Longby tangman116
BMY Hidden Bearish DivergenceStill within descending triangle pattern and showing Hidden Bearish DivergenceShortby sweenejo2
BMY moved slightly above long-term trendline going into earningsBMY is slightly above its long-term trend line. It doesn't appear to have breakout volume right now, but the move implies investor optimism about tomorrow's earnings. Zacks has given BMY a positive earnings surprise prediction.Longby ChristopherCarrollSmithUpdated 7
BMY still BearishBearish -Descending Triangle -bearish divergence Bullish -At historic support level -30th September expiration date of the offers to exchange (Celgene) could see a trend reversal by sweenejo1
BMY Huge OI for September Calls @ $50 and $48Bristol Myers Sept.Calls bought by the thousands. So, why not? Longby BlokkyClub2
BMY Is starting a bull moveHey everyone, Another biomed related post today by request. BMY has double-bottomed as bulls grab a little control today on price. The stock has respected the BBands and is looking to move to the neutral region. The RSI teased in the oversold area, and price has responded with one of the two strong bull movements in the past four weeks as far as price movement goes. Price will struggle to break the $48.31 resistance that the massive bull volume failed to break on the 29th. We want to look for increasing bull volume as price recovers after hitting a low. If bull volume recovers with the next successive days, look at the $48.31 target for the first movement, with the $54 mark if price breaks through for the second movement. If bear volume trends or increasing in the next few days below the 45.15 support, the stock could break lower forming new lows for the year. Keep a tight stop loss in the meantime at the lower $45.15 support and long for the 48.31 and eventually the 54.44 if price starts to trend up with volume or if it ventures beyond the restraints of the BBands. -BlockLongby block21e8Updated 3
$BMY Inside BoxLooks like a contender for a Bullish Spread. $SPY $QQQ $DIA #StockstoWatch #StockMarket #Optionsby josen6260
$BMY Bristol Myers ready for a BULLISH moveBristol-Myers Squibb upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket. Post earnings BMY has had some nice price action, investors liked what the heard from the earnings report and the analysts have started to upgrade the stock as of today. Sentiment in the Pharma sector has been horrendous for months, so maybe a turnaround is on the cards. The price has found a bottom and the indicators have also put a strong base in. We think this is a very safe long with a good RR opportunity. Company Description Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics Longby RedHotStocks4
Regular Bullish Divergence for BMY stockRegular Bullish Divergence for BMY stock. Have we reached the bottom? Longby sweenejo0
BMY is approaching support, potential bounce! BMY is approaching our first support at 47.85 where we might see a bounce in price to our resistance at 51.12. Stochastic is also approaching support where we might see a corresponding bounce in price. Longby TradeGATEHub39
May 17 - BMYBMY 17-May-19 IV30:41.7, IVR:99 (Elevated), IV30 MA20: 35.4 Bear Call Spread +0.19D Long 1 Call: 57.5 Strike @ $0.80 -0.28D Short 1 Call: 55 Strike @ $1.29 -0.09D Credit: $0.49 Shortby imzeeshan0